Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Public ClinicalTrials.gov record NCT03732820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
Study identification
- NCT ID
- NCT03732820
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 895 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2018 (Actual)
- Primary completion
- Jul 30, 2021 (Actual)
- Completion
- Feb 5, 2027 (Estimated)
- Last update posted
- Aug 18, 2026
2018 – 2027
United States locations
- U.S. sites
- 28
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35209 | — |
| Research Site | Anchorage | Alaska | 99503 | — |
| Research Site | Tucson | Arizona | 85704 | — |
| Research Site | Tucson | Arizona | 85741 | — |
| Research Site | Clovis | California | 93611 | — |
| Research Site | Los Angeles | California | 90027 | — |
| Research Site | Los Angeles | California | 90073 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | San Diego | California | 92123 | — |
| Research Site | Denver | Colorado | 80211 | — |
| Research Site | Lisle | Illinois | 60532 | — |
| Research Site | Jeffersonville | Indiana | 47130 | — |
| Research Site | New Orleans | Louisiana | 70112 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | St Louis | Missouri | 63106 | — |
| Research Site | Bozeman | Montana | 59715 | — |
| Research Site | Omaha | Nebraska | 68130 | — |
| Research Site | Paramus | New Jersey | 07652 | — |
| Research Site | Brooklyn | New York | 11220 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Myrtle Beach | South Carolina | 29572 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03732820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03732820 live on ClinicalTrials.gov.